JPH0526800B2 - - Google Patents
Info
- Publication number
- JPH0526800B2 JPH0526800B2 JP58053922A JP5392283A JPH0526800B2 JP H0526800 B2 JPH0526800 B2 JP H0526800B2 JP 58053922 A JP58053922 A JP 58053922A JP 5392283 A JP5392283 A JP 5392283A JP H0526800 B2 JPH0526800 B2 JP H0526800B2
- Authority
- JP
- Japan
- Prior art keywords
- rheumatoid
- patients
- plasma
- mobility
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000009027 Albumins Human genes 0.000 claims description 9
- 108010088751 Albumins Proteins 0.000 claims description 9
- 238000001962 electrophoresis Methods 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 claims description 3
- 239000000499 gel Substances 0.000 description 19
- 238000000034 method Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 12
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 12
- 238000003745 diagnosis Methods 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000004255 ion exchange chromatography Methods 0.000 description 5
- 208000019423 liver disease Diseases 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229920000298 Cellophane Polymers 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 238000009666 routine test Methods 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 101710100170 Unknown protein Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58053922A JPS59180363A (ja) | 1983-03-31 | 1983-03-31 | リウマチ特異蛋白質 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58053922A JPS59180363A (ja) | 1983-03-31 | 1983-03-31 | リウマチ特異蛋白質 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP24249090A Division JPH03218464A (ja) | 1990-09-14 | 1990-09-14 | リウマチ特異蛋白質に対する抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59180363A JPS59180363A (ja) | 1984-10-13 |
| JPH0526800B2 true JPH0526800B2 (enrdf_load_stackoverflow) | 1993-04-19 |
Family
ID=12956206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58053922A Granted JPS59180363A (ja) | 1983-03-31 | 1983-03-31 | リウマチ特異蛋白質 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS59180363A (enrdf_load_stackoverflow) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6216499A (ja) * | 1985-07-16 | 1987-01-24 | Asahi Medical Co Ltd | 抗リウマチ特異蛋白質モノクロ−ナル抗体および細胞株 |
| US4742157A (en) * | 1984-09-14 | 1988-05-03 | Asahi Medical Co., Ltd. | Substantially pure rheumatoid arthritis specific protein and an antibody against the same |
-
1983
- 1983-03-31 JP JP58053922A patent/JPS59180363A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS59180363A (ja) | 1984-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kawai | Clinical aspects of the plasma proteins | |
| Diaz et al. | Bullous pemphigoid antigen: isolation from normal human skin | |
| James et al. | Studies on a unique diagnostic serum globulin in papular mucinosis (lichen myxedematosus) | |
| JPS59225196A (ja) | 組織蛋白質およびその単離法 | |
| NO303852B1 (no) | FremgangsmÕte ved pÕvisning av analyttvarianter, samt sett for utf°relse av fremgangsmÕten | |
| Merlini et al. | A human myeloma immunoglobulin G binding four moles of calcium associated with asymptomatic hypercalcemia | |
| Brandtzaeg | HUMAN SECRETORY IMMUNOGLOBULINS: 4. Quantitation of Free Secretory Piece | |
| EP0313156B1 (en) | Snrnp-a antigen and fragments thereof | |
| JPS62501563A (ja) | リウマチ性関節炎の特徴である蛋白質 | |
| JPH0354679B2 (enrdf_load_stackoverflow) | ||
| Tschopp et al. | Occurrence of an incomplete C8 molecule in homozygous C8 deficiency in man. | |
| JPH0678788A (ja) | 骨ぜい弱性と骨粗しょう症骨折の危険性の検査方法 | |
| CA2071530A1 (en) | Diagnosis of glomerulonephritis | |
| Kaplan et al. | Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma: a pilot study of intact and truncated forms of light chains and their charge properties | |
| Kitamura et al. | Immunochemical analysis of the monoclonal paraprotein in scleromyxedema. | |
| Green et al. | Urinary loss of clotting factors due to hereditary membranous glomerulopathy | |
| JPH0526800B2 (enrdf_load_stackoverflow) | ||
| JPH0541640B2 (enrdf_load_stackoverflow) | ||
| Moroz et al. | A hereditary immunoglobulin A abnormality: absence of light-heavy—chain assembly: Study of immunoglobulin synthesis in tonsillar cells | |
| Glueck et al. | A monoclonal immunoglobulin A (κ) factor VIII: C inhibitor associated with primary amyloidosis: Identification and characterization | |
| JPH0523280B2 (enrdf_load_stackoverflow) | ||
| JP2915530B2 (ja) | ラミニン フラグメント | |
| WO1986000924A1 (en) | Process for preparing human proline hydroxylase | |
| JP3165828B2 (ja) | 悪性腫瘍の検出方法及びキット | |
| Ayala et al. | Immunochemical characterization of the abnormal paraprotein in a case of scleromyxoedema |